Skip Navigation


NDT Advance Access originally published online on June 9, 2006
Nephrology Dialysis Transplantation 2006 21(8):2065-2068; doi:10.1093/ndt/gfl289
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/8/2065    most recent
gfl289v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Savica, V.
Right arrow Articles by Bellinghieri, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Savica, V.
Right arrow Articles by Bellinghieri, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Editorial Review

Phosphate binders and management of hyperphosphataemia in end-stage renal disease

Vincenzo Savica1, Lorenzo A. Calò2, Pietro Monardo1, Domenico Santoro1 and Guido Bellinghieri1

1 Chairs of Nephrology, University of Messina and Nephrology Dialysis Unit ‘Papardo’ Hospital, Messina and 2 Department of Clinical and Experimental Medicine, Clinica Medica 4, University of Padova, Padova, Italy

Correspondence and offprint requests to: Lorenzo A. Calò MD, PhD, Department of Clinical and Experimental Medicine, Clinica Medica 4, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy. Email: renzcalo@unipd.it

Keywords: hyperphosphataemia; phosphate binders; renal failure; vascular calcifications

The first 150 words of the full text of this article appear below.

Hyperphosphataemia is a known factor contributing to the increased risk of cardiac death both in patients with end-stage renal disease (ESRD) and in those under renal replacement treatment with dialysis [1,2]. In patients with renal disease, in fact, the well-known relationship between hyperphosphataemia, secondary hyperparathyroidism, bone turnover and extra osseous calcifications has recently been followed by the recognition of a major role played by elevated serum phosphate levels in the induction of vascular calcification [3–5], cardiac interstitial fibrosis and arterial thickening [6] which highly increase the risk of cardiac death [1,2]. In response to these findings, the National Kidney Foundation Kidney Disease Outcome Quality Initiative (K/DOQI) Clinical Practice Guidelines for bone metabolism and disease in chronic kidney disease has recently recommended that more stringent levels for controlling serum phosphorus (serum phosphorus levels be maintained between 3.5 and 5.5 . . . [Full Text of this Article]



   Management of hyperphosphataemia in ESRD patients
 
Dietary approach to phosphate retention
Dialysis
Phosphate-binding agents
Newly developed compounds
Sevelamer hydrochloride
Lanthanum carbonate
Trivalent iron preparations


   Conclusions
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
V. Savica, L. A. Calo, P. Monardo, P. A. Davis, A. Granata, D. Santoro, R. Savica, R. Musolino, M. C. Comelli, and G. Bellinghieri
Salivary Phosphate-Binding Chewing Gum Reduces Hyperphosphatemia in Dialysis Patients
J. Am. Soc. Nephrol., March 1, 2009; 20(3): 639 - 644.
[Abstract] [Full Text] [PDF]